Results 221 to 230 of about 620,136 (263)
CAR-NK cell for gynecological cancers: immune microenvironment remodeling and immunotherapeutic strategies. [PDF]
Huang M, Wang S, Huang H, Li L, Wang T.
europepmc +1 more source
Bone Organoids: A Novel Tool for Modeling and Managing Skeletal Disorders in Diabetes
This review synthesizes advances in bone organoid engineering and evaluates their potential to model diabetic bone fragility. Current in vitro and animal models do not fully recapitulate diabetes‐associated skeletal phenotypes. Cell‐based and scaffold‐based bone organoids are discussed as complementary approaches to reconstruct multicellular bone ...
Shuangzhe Lin +2 more
wiley +1 more source
Integrating Single-Cell and Spatial Transcriptomics Reveals NK Cell Subpopulations Associated With Immunotherapy for Melanoma. [PDF]
Hu Z +9 more
europepmc +1 more source
High‐grade serous ovarian carcinoma (HGSOC) is plagued by platinum resistance, with malignant ascites closely linked to poor outcomes. Here, we identify ASCOR, a circRNA enriched in ascites small extracellular vesicles (sEVs) from platinum‐resistant HGSOC patients, as a predictor of poor survival. ASCOR enhances platinum resistance in vitro and in vivo
Hanyuan Liu +10 more
wiley +1 more source
Leveraging the heterogeneity of the NK cell repertoire for the development of immunotherapies for acute leukemia. [PDF]
Ferron E +3 more
europepmc +1 more source
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey +6 more
wiley +1 more source
Enhancing NK Cell Activity in Colorectal Cancer with an Fc-Optimized Antibody Targeting CD276 (B7-H3). [PDF]
Stefańczyk SA +7 more
europepmc +1 more source
NK Cell Activation by Platinum Boosts Immunotherapy in HR+/HER2− Breast Cancer
Multi‐omics and single‐cell analyses identify activated NK cells as key mediators of anti‐PD‐(L)1 response in HR+/HER2− breast cancer. Platinum chemotherapy enhances NK cell cytotoxicity through NF‐κB–associated signaling, synergizing with immunotherapy and providing a rationale for combination treatment.
Yi‐Yu Chen +8 more
wiley +1 more source

